Update on cardiovascular disease in post-menopausal women

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 16, Issue 3, 2002, Pages 329-355

  Gorodeski, George I ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Cardiovascular disease; Oestrogen; Risk factors; Women

Indexed keywords

ESTROGEN; SEX HORMONE; PROGESTERONE DERIVATIVE;

ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; ESTROGEN ACTIVITY; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; HEART ARRHYTHMIA; HEART AUTOMATICITY; HUMAN; HYPERTENSION; LIFESTYLE; MORBIDITY; MORTALITY; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; AGED; BLOOD VISCOSITY; FEMALE; HYPERLIPIDEMIA; MALE; MENTAL STRESS; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR; SEX; SMOKING;

AGED; BLOOD VISCOSITY; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LIFE STYLE; MALE; MIDDLE AGED; OBESITY; POSTMENOPAUSE; PROGESTERONE CONGENERS; RISK FACTORS; SEX; SMOKING; STRESS, PSYCHOLOGICAL;

EID: 0036597219     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2002.0282     Document Type: Article

References (319)

1. Anderson RN, Kochanek KD & Murphy SL. Report of final mortality statistics. 1995. Monthly Vital Statistics Report 1997; 45 (supplement 2): 23-33 (table 7).
2. Advance report of final mortality statistics. 1989. Monthly Vital Statistics Report 1992; 40 (supplement 2): 1-47.
3. NIH: Chartbook on Cardiovascular, Lung and Blood Diseases. US Department of Health and Human Services, 1992. May.
4. Manson JE, Tosteson H, Ridker PM et al. The primary prevention of myocardial infarction. New England Journal of Medicine 1992; 326: 1406-1416.
5. Bush TL. The epidemiology of cardiovascular disease in postmenopausal women. Annals of the New York Academy of Sciences 1990; 592: 263-271.
6. Miller VT. Dyslipoproteinemia in women: special considerations. Endocrinology and Metabolism Clinics of North America 1990; 19: 381-398.
7. Halm MA & Penque S. Heart failure in women. Progress in Cardiovascular Nursing 2000; 15: 121-133.
8. Kalin MF & Zumoff B. Sex hormones and coronary disease: a reveiw of the clinical studies. Steroids 1990; 55: 330-352.
9. Kannell WB & Feinleib M. Natural history of angina pectoris in the Framingham study: prognosis and survival. American Journal of Cardiology 1972; 29: 154-163.
10. Kannel WB & Abbott RD. Incidence and prognosis of unrecognized myocardial infarction: an update on the Framingham study. New England Journal of Medicine 1984; 311: 1144-1147.
11. American Heart Association. 1993 Heart and Stroke Facts. Dallas: American Heart Association National Center, 1993.
12. Rosenfeld AG. Women's risk of decision delay in acute myocardial infarction: implications for research and practice. American Association of Clinical Nurses Clinical Issues 2001; 12: 29-39.
13. Wenger NK. Gender, coronary artery disease, and coronary bypass surgery. Annals of Internal Medicine 1990; 112: 557-558.
14. Kessler KM. Syndrome X: the epicardial view. Journal of the American College of Cardiology 1992; 19: 32-33.
15. Ayanian JZ & Epstein AM. Differences in the use of procedures between women and men hospitalized for coronary heart disease. New England Journal of Medicine 1991; 325: 222-225.
16. Steingart RM, Packer M, Hamm P et al. Sex differences in the management of coronary artery disease. New England Journal of Medicine 1991; 325: 226-230.
17. Maynard C, Litwin PE, Martin JS & Weaver WD. Gender differences in the treatment and outcome of acute myocardial infarction. Archives of Internal Medicine 1992; 152: 972-976.
18. Kahn SS, Nessim S, Gray R et al. Increased mortality of women in coronary artery bypass surgery: evidence for referral bias. Annals of Internal Medicine 1990; 112: 561-567.
19. Loop FD, Golding LR, MacMillan JP et al. Coronary artery surgery in women compared with men: analyses of risks and long term results. Journal of the American College of Cardiology 1983; 1: 383-390.
20. Shaw LJ, Hachamovitch R & Redberg RF. Current evidence on diagnostic testing in women with suspected coronary artery disease: choosing the appropriate test. Cardiology Review 2000; 8: 65-74.
21. Chirikos TN & Nickel JL. Work disability from coronary heart disease in women. Women's Health 1984; 9: 55-74.
22. Tofler G, Stone P & Muller J. Effect of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women. Journal of the American College of Cardiology 1987; 9: 473-482.
23. Hayward CS, Webb CM & Collins P. Effect of sex hormones on cardiac mass. Lancet 2001; 357: 1354-1356.
24. Jairath N. Implications of gender differences on coronary artery disease risk reduction in women. American Association of Clinical Nurses Clinical Issues 2001; 12: 17-28.
25. Fuster V, Badimon L, Badimon JJ & Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (I). New England Journal of Medicine 1992; 326: 242-250.
26. Fuster V, Badimon L, Badimon JJ & Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (II). New England Journal of Medicine 1992; 326: 310-318.
27. Vane JR, Anggaard EE & Botting RM. Regulatory functions of the vascular endothelium. New England Journal of Medicine 1990; 323: 27-36.
28. Endothelins. Lancet 1991; 337: 79-81.
29. Ernst E, Matrai A & Marshall M. Blood rheology in patients with ischemic attacks. Stroke 1988; 19: 634-636.
30. Resch KL, Ernst E, Matrai A & Paulson HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Annals of Internal Medicine 1992; 117: 371-375.
31. Malloy KJ & Bahinski A. Cardiovascular disease and arrhythmias: unique risks in women. Journal of Gender Specific Medicine 1999; 2: 37-44.
32. Kaufman ES, Priori SG, Napolitano C et al. Electrocardiographs prediction of abnormal genotype in congenital long QT syndrome: experience in 101 related family members. Journal of Cardiovascular Electrophysiology 2001; 12: 455-461.
33. Legato MJ. Gender and the heart: sex-specific differences in normal anatomy and physiology. Journal of Gender Specific Medicine 2000; 3: 15-18.
34. Lee PY, Alexander KP, Hammill BG et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. Journal of the American Medical Association 2001; 286: 708-713.
35. Hubert HB, Feinlab M, McNamara PM & Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26 year follow-up of participants in the Framingham heart study. Circulation 1983; 67: 968-977.
36. Harlan WR, Landis JR, Flegal KM et al. Secular trends in body mass in the U.S., 1960-1980. American Journal of Epidemiology 1988; 128: 1065-1074.
37. Manson JE, Colditz GA, Stampfer MJ et al. A prospective study of obesity and risk of coronary heart disease in women. New England Journal of Medicine 1990; 322: 882-889.
38. Wing RR, Mathews KA, Kuller LH et al. Weight gain at the time of menopause. Archives of Internal Medicine 1991; 151: 97-102.
39. Martin ML & Jensen MD. Effects of body fat distribution on regional lipolysis in obesity. Journal of Clinical Investigation 1991; 88: 609-613.
40. Larsson B, Bengtsson C, Bjorntorp P et al. Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? American Journal of Epidemiology 1992; 135: 266-273.
41. Zamboni M, Armellini F, Milani MP et al. Body fat distribution in pre and postmenopausal women: metabolic and anthropometric variables and their interrelationships. International Journal of Obesity Related Metabolic Disorders 1992; 16: 495-504.
42. Jensen DM, Haymond MW, Rizza RA et al. Influence of body fat distribution on free fatty acid metabolism in obesity. Journal of Clinical Investigation 1989; 83: 1168-1173.
43. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Archives of Internal Medicine 1988; 148: 36-49.
44. Jacobs DR, Mebane IL, Bangdiwala SI et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. American Journal of Epidemiology 1990; 131: 32-47.
45. Lerner DJ & Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes. A 26 year follow-up of the Framingham population. American Heart Journal 1986; 111: 383-390.
46. Chen Z, Peto R, Collins R et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentration. British Medical Journal 1991; 303: 276-282.
47. Levy RI, Brensike JF, Epstein SE et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease. Circulation 1984; 69: 325-337.
48. Arntzenius AC, Kromhont D, Barth JD et al. Diet, lipoproteins and the progression of coronary atherosclerosis. New England Journal of Medicine 1985; 312: 805-811.
49. Blankenhorn DH, Nessin SA, Johnson RL et al. Beneficial aspects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass graft. Journal of the American Medical Association 1987; 257: 3233-3240.
50. Austin MA. Plasma triglyceride as a risk factor for coronary heart disease. American Journal of Epidemiology 1989; 129: 249-259.
51. Matthews KA, Meilahn E, Kuller LH et al. Menopause and risk factors for coronary heart disease. New England Journal of Medicine 1989; 321: 641-646.
52. Jensen J, Nilas L & Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990; 12: 321-331.
53. Talbott EO, Zborowski JV, Sutton-Tyrrell K et al. Cardiovascular risk in women with polycystic ovary syndrome. Obstetrics and Gynecology Clinics of North America 2001; 28: 111-133.
54. Wild RA, Painter PC, Coulson PB et al. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1985; 61: 946-951.
55. Wild RA, Alanpovic P, Givens JR & Parker IJ. Lipoprotein abnormalities in hirsute women. American Journal of Obstetrics and Gynecology 1992; 167: 1813-1818.
56. Schuler G, Hambrecht R, Schlierf G et al. Regular physical exercise and low fat diet. Circulation 1992; 86: 1-11.
57. Working group on hypertension in the elderly. Statement on hypertension in the elderly. Journal of the American Medical Association 1986; 256: 70-74.
58. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke and coronary heart disease. Lancet 1990; 335: 765-774.
59. Dittrich H, Gilpin E, Nicol P et al. Acute myocardial infarction in women: influence of gender on mortality and prognostic variables. American Journal of Cardiology 1988; 62: 1-7.
60. Kannel WB, Wilson PWF & Zhang TJ. The epidemiology of impaired glucose tolerance and hypertension. American Heart Journal 1991; 121: 1268-1273.
61. Isles CG, Hole DJ, Hawthorne VM & Lever AF. Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley Survey: comparison with men. Lancet 1992; 339: 702-706.
62. Barrett-Connor E & Wingard DL. Sex differential in ischemic heart disease mortality in diabetics. American Journal of Epidemiology 1983; 118: 489-496.
63. Ford ES & DeStefano F. Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. American Journal of Epidemiology 1991; 133: 1220-1230.
64. Despres J-P, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. New England Journal of Medicine 1996; 334: 952-957.
65. Reaven GM & Greenfield MS. Diabetic hypertriglyceridemia, evidence for the clinical syndromes. Diabetes 1981; 30 (supplement): 66-75.
66. Manson JE, Rimm EB, Stampfer MJ et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 1991; 338: 774-778.
67. Bush TL & Comstock CW. Smoking and cardiovascular mortality in women. American Journal of Epidemiology 1983; 118: 480-488.
68. Rosenberg L, Kaufman DW, Helmrich SP et al. Myocardial infarction and cigarette smoking in women younger than 50 years of age. Journal of the American Medical Association 1985; 253: 2965-2969.
69. LaCroix AZ, Lang J, Scherr P et al. Smoking and mortality among older men and women in three communities. New England Journal of Medicine 1991; 324: 1619-1625.
70. Department of Health and Human Services. Reducing the Health Consequences of Smoking: 25 Years of Progress. A Report of the Surgeon General. Washington, DC: Government Printing Office, 1989 (DHHS publication no. CDC 89-8411).
71. Willett WC, Green A, Stampfer MJ et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. New England Journal of Medicine 1987; 317: 1303-1309.
72. Craig WY, Palomaki GE & Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentration: an analysis of published data. British Medical Journal 1989; 298: 784-788.
73. Palmer Jr, Rosenberg L & Shapiro S. 'Low Yield' cigarettes and the risk of nonfatal myocardial infarction in women. New England Journal of Medicine 1989; 320: 1569-1573.
74. Muscat JE, Harris RE, Haley NJ & Wynder EL. Cigarette smoking and plasma cholesterol. American Heart Journal 1991; 121: 141-147.
75. Mjos OD. Lipid effects of smoking. American Heart Journal 1988; 115: 272-275.
76. Schoenberger JC. Smoking change in relation to changes in blood pressure, weight and cholesterol. Preventive Medicine 1982; 11: 441-453.
77. Davis JW & Davis RF. Acute effects of tocacco cigarette smoking on the platelet aggregate ratio. American Journal of Medical Science 1979; 278: 139-143.
78. Markowe HLJ, Marmot MG, Shipley MJ et al. Fibrinogen: a possible link between social class and coronary heart disease. British Medical Journal 1985; 291: 1312-1314.
79. Facchini FS, Hollenbeck CB, Jeppesen J et al. Insulin resistance and cigarette smoking. Lancet 1992; 339: 1128-1130.
80. Daniel M, Martin AD & Faiman C. Sex hormones and adipose tissue distribution in premenopausal cigarette smokers. International Journal of Obesity 1992; 16: 245-254.
81. Keil DP, Baron JA, Anderson JJ et al. Smoking eliminates the protective effect of oral estrogens on the risk for hip fracture among women. Annals of Internal Medicine 1992; 116: 716-721.
82. Jensen J, Christiansen C & Rodbro P. Cigarette smoking, serum estrogens and bone loss during hormone replacement therapy early after menopause. New England Journal of Medicine 1985; 313: 973-975.
83. Hartz AJ, Kelber S, Borkowf H et al. The association of smoking with clinical indicators of altered sex steroids-a study of 50,145 women. Public Health Report 1987; 102: 254-259.
84. Lesko SM, Rosenberg L, Kaufman DW et al. Cigarette smoking and the risk of endometrial cancer. New England Journal of Medicine 1985; 313: 593-596.
85. Baron JA, La Vecchia C & Levi F. The antiestrogenic effect of cigarette smoking in women. American Journal of Obstetrics and Gynecology 1990; 162: 502-514.
86. Barbieri RL, McShane RM & Ryan KJ. Constituents of cigarette smoke inhibit human granulosa cell aromatase. Fertility and Sterility 1986; 46: 232-236.
87. Michnovicz JJ, Hershcopf RJ, Naganuma H et al. Increased 2-hydroxylation of estradiol as a possible mechanism for the antiestrogenic effect of cigarette smoking. New England Journal of Medicine 1986; 315: 1305-1309.
88. Rosenberg L, Palmer JR & Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. New England Journal of Medicine 1990; 322: 213-217.
89. Oja P. Dose response between total volume of physical activity and health and fitness. Medicine and Science in Sports Exercise 2001; 33(6 supplement): S428-S437.
90. Sallis JF, Patterson TL, Buono MJ & Nader PR. Relation of cardiovascular fitness and physical activity to cardiovascular risk factors in children and adults. American Journal of Epidemiology 1988; 127: 933-941.
91. Considine RV. Invited editorial on 'Acute and chronic effects of exercise on leptin levels in humans'. Journal of Applied Physiology 1997; 83: 3-4.
92. Owens JF, Matthews KA, Wing RR & Kuller LH. Can physical activity mitigate the effects of aging in middle aged women? Circulation 1992; 85: 1265-1270.
93. Fraser GE, Strahan TM, Sabate J et al. Effects of traditional coronary risk factors on rates of incident coronary events in a low risk population. Circulation 1992; 86: 406-413.
94. Hunt BJ. The relation between abnormal hemostatic function and the progression of coronary disease. Current Opinion in Cardiology 1990; 5: 758-765.
95. Scarabin PY, Kopp CB, Bara L et al. Factor VII activation and menopausal status. Thrombosis Research 1990; 57: 227-234.
96. Herd JA. Cardiovascular response to stress. Physiological Reviews 1991; 71: 305-330.
97. Tofler GH, Brezinski D, Schafer AI et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. New England Journal of Medicine 1987; 316: 1514-1518.
98. Panza JA, Epstein SE & Quyyumi AA. Circadian variation in vascular tone and its relation to sympathetic vasoconstrictor activity. New England Journal of Medicine 1991; 325: 986-990.
99. Manfredini R, Gallerani M, Portaluppi F & Fersini C. Relationships of the circadian rhythms of thrombotic, ischemic, hemorrhagic, and arrhythmic events to blood pressure rhythms. Annals of the New York Academy of Sciences 1996; 783: 141-158.
100. Ballinger SE & Walker WL. Not THE change of life: Breaking the Menopause Taboo. Ringwood, Victoria, Australia: Penguin, 1987.
101. Ballinger S. Stress as a factor in lowered estrogen levels in the early postmenopause. Annals of the New York Academy of Sciences 1990; 592: 95-113.
102. Woods NF, Derby GK & Most A. Stressful life events and perimenstrual symptoms. Journal of Human Stress 1982; 8: 23-31.
103. Rosano GM, Patrizi R, Leonardo F et al. Effect of estrogen replacement therapy on heart rate variability and heart rate in healthy postmenopausal women. American Journal of Cardiology 1997; 80: 815-817.
104. Lipsitz LA, Connelly CM, Kelley-Gagnon M et al. Effects of chronic estrogen replacement therapy on beat-to-beat blood pressure dynamics in healthy postmenopausal women. Hypertension 1995; 26: 711-715.
105. Davy KP, Miniclier NL, Taylor JA et al. Elevated heart rate variability in physically active postmenopausal women: a cardioprotective effect? American Journal of Physiology 1996; 271: H455-H460.
106. Kannel WB, Hjortland MC, McNamara PM & Gordon T. The Framingham Study. Menopause and risk of cardiovascular disease. Annals of Internal Medicine 1976; 85: 447-452.
107. Colditz GA, Willett WC, Stampfer MJ et al. A prospective study of age at menarche, parity, age at first birth and coronary heart disease in women. American Journal of Epidemiology 1987; 126: 861-870.
108. LaVecchia C, Decarli A, Franceschi S et al. Menstrual and reproductive factors and risk of myocardial infarction in women under 55 years of age. American Journal of Obstetrics and Gynecology 1987; 157: 1108-1112.
109. Beard CM, Kottke TE, Annegers JF & Ballard DJ. The Rochester Coronary Heart Disease Project: effect of cigarette smoking, hypertension, diabetes and steroidal estrogen use on coronary heart disease among 40 to 59 year-old women, 1960 through 1982. Mayo Clinic Proceedings 1989; 64: 1471-1480.
110. Stampfer MJ & Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive Medicine 1991; 20: 47-63.
111. Potocki J. Wplyw leczenia estrogenami na niewydolnose wiencowa u kobiet po menopauzie. Polski Tygodnik Lekarski 1971; 26: 1812-1815.
112. Burch JC, Byrd BF Jr & Vaughn WK. The effects of long-term estrogen on hysterectomized women. American Journal of Obstetrics and Gynecology 1974; 188: 778-782.
113. Talbott E, Kuller LH, Detre K & Perper J. Biologic and psychosocial risk factors of sudden death from coronary disease in white women. American Journal of Cardiology 1977; 39: 858-864.
114. Jick H, Dinan B, Herman R & Rothman KJ. Myocardial infarction and other vascular diseases in young women: Role of estrogens and other factors. Journal of the American Medical Association 1978; 240: 2548-2552.
115. Pfeffer RI, Whipple GH, Kurosaki TT & Chapman JM. Coronary risk and estrogen use in postmenopausal women. American Journal of Epidemiology 1978; 107: 479-487.
116. MacMahon B. Cardiovascular disease and noncontraceptive oestrogen therapy. In Oliver MF (ed.) Coronary Heart Disease in Young Women, pp 197-207. New York: Churchill Livingstone, 1979.
117. Hammond CB, Jelovsek FR, Lee LK et al. Effects of long-term estrogen replacement therapy. I. Metabolic effects. American Journal of Obstetrics and Gynecology 1979; 133: 525-536.
118. Nachtigall LE, Nachtigall RH, Nachtigall RD & Beckman EM. Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics and Gynecology 1979; 54: 74-79.
119. Adam S, Williams V & Vessey MP. Cardiovascular disease and hormone replacement treatment: a pilot case-control study. British Medical Journal 1981; 282: 1277-1278.
120. Bain C, Willett WC, Hennekens CH et al. Use of postmenopausal hormones and risk of myocardial infarction. Circulation 1981; 64: 42-46.
121. Ross RK, Paganini-Hill A, Mack TM et al. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981; i: 858-860.
122. Szklo M, Tonascia J, Gordis L & Bloom I. Estrogen use and myocardial infarction risk: a case-control study. Preventive Medicine 1984; 13: 510-516.
123. Lafferty FW & Helmuth DO. Postmenopausal estrogen replacement: the prevention of osteoporosis and systemic effects. Maturitas 1985; 7: 147-159.
124. Bush TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102-1109.
125. Hunt K, Vessey M, McPherson K & Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. British Journal of Obstetrics and Gynaecology 1987; 94: 620-635.
126. Petitti DB, Perlman JA & Sidney S. Noncontraceptive estrogens and mortality: Long-term follow-up of women in the Walnut Creek Study. Obstetrics and Gynecology 1987; 70: 289-293.
127. Criqui MH, Suarez L, Barrett-Connor E et al. Postmenopausal estrogen use and mortality. American Journal of Epidemiology 1988; 128: 606-614.
128. Gruchow HW, Anderson AJ, Barboriak JJ & Sobocinski KA. Postmenopausal use of estrogen and occlusion of coronary arteries. American Heart Journal 1988; 115: 954-963.
129. McFarland KF, Boniface ME, Hornung CA et al. Risk factors and noncontraceptive estrogen use in women with and without coronary disease. American Heart Journal 1989; 117: 1209-1214.
130. Croft P & Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraceptive study. British Medical Journal 1989; 298: 165-168.
131. Avila MH, Walker AM & Jick H. Use of replacement estrogens and the risk of myocardial infarction. Epidemiology 1990; 1: 128-133.
132. Sullivan JM, Vander Zwaag R, Hughes JP et al. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Archives of Internal Medicine 1990; 150: 2557-2562.
133. Henderson BE, Paganini-Hill A & Ross RK. Decreased mortality in users of estrogen replacement therapy. Archives of Internal Medicine 1991; 151: 75-78.
134. Stampfer MJ, Colditz GA & Willett WC. Postmenopausal estrogen therapy and cardiovascular disease: ten year follow-up from the Nurses' Health Study. New England Journal of Medicine 1991; 325: 756-762.
135. Wolf PH, Madans JH, Finucane FF et al. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. American Journal of Obstetrics and Gynecology 1991; 164: 489-494.
136. Falkeborn M, Persson I & Adami HO. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen therapy. British Journal of Obstetrics and Gynaecology 1992; 99: 821-828.
137. Rosenberg L, Armstrong B & Jick H. Myocardial infarction and estrogen therapy in postmenopausal women. New England Journal of Medicine 1976; 294: 1256-1259.
138. Thompson SG, Meade TW & Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. Journal of Epidemiology and Community Health 1989; 43: 173-178.
139. Jick H, Dinan B & Rothman KJ. Noncontraceptive estrogens and nonfatal myocardial infarction. Journal of the American Medical Association 1978; 239: 1407-1408.
140. Rosenberg L, Stone D, Shapiro S et al. Noncontraceptive estrogens and myocardial infarction in young women. Journal of the American Medical Association 1980; 244: 339-342.
141. Wilson PW, Garrison RJ & Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. New England Journal of Medicine 1985; 313: 1038-1043.
142. LaVecchia C, Franceschi S, Decarli A et al. Risk factors for myocardial infarction in young women. American Journal of Epidemiology 1987; 125: 832-843.
143. Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. New England Journal of Medicine 1996; 335: 453-461.
144. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Annals of Internal Medicine 1991; 115: 455-456.
145. Grodstein F, Stampfer MJ, Colditz GA et al. Postmenopausal hormone therapy and mortality. New England Journal of Medicine 1997; 336: 1769-1775.
146. Walsh BW, Schiff I, Rosner B et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New England Journal of Medicine 1991; 325: 1196-1204.
147. Sacks FM, McPherson R & Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Archives of Internal Medicine 1994; 154: 1106-1110.
148. Bruckert E & Turpin G. Estrogens and progestins in postmenopausal women, influence on lipid parameters and cardiovascular risk. Hormone Research 1995; 43: 100-103.
149. Haines CJ, Chung TK, Masarei JR et al. The effect of percutaneous oestrogen replacement therapy on Lp(a) and other lipoproteins. Maturitas 1995; 22: 219-225.
150. Haines CJ, Chung TK, Masarei JR et al. An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins. Atherosclerosis 1996; 119: 215-222.
151. Kim CJ, Min YK, Ryu WS et al. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy. Archives of Internal Medicine 1996; 156: 1693-1700.
152. Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 1997; 95: 329-334.
153. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions PEPI Trial. Journal of the American Medical Association 1995; 273: 199-208.
154. Ludmer PL, Selwyn AP, Shook TL et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. New England Journal of Medicine 1987; 315: 1046-1051.
155. Kovanen PT, Brown MS & Goldstein JL. Increased binding of low density lipoprotein to liver membranes from rats treated with 17β ethinyl estradiol. Journal of Biological Chemistry 1979; 254: 11 367-11 373.
156. Tikkanen MJ, Nikkila EA, Kuusi T & Sipinen S. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. Journal of Clinical Endocrinology and Metabolism 1982; 54: 1113-1117.
157. Berenson GS, Wattigney WA, Tracy RE et al The Bogalusa Heart Study. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy. American Journal of Cardiology 1992; 70: 851-858.
158. Vlodaver Z, Kahn HA & Neufeld HN. The coronary arteries in early life in three different ethnic groups. Circulation 1979; 39: 541-550.
159. Neufeld HN, Wagenvoort CA & Edwards JE. Coronary arteries in fetuses, infants, juveniles and young adults. Laboratory Investigation 1962; 11: 837-844.
160. Szczeklik A, Gryglewski RJ, Domagala B et al. Dietary supplementation with vitamin E in hyperlipoproteinemias: effects on plasma lipid peroxides, antioxidant activity, prostacyclin generation and platelet aggregability. Thrombosis and Haemostasis 1985; 54: 425-430.
161. Everson GT, McKinley G & Kern F. Mechanisms of gallstone formation in women. Journal of Clinical Investigation 1991; 87: 237-246.
162. Wagner JD, Clarkson TB, St Clair RW et al. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal Cynomolgus monkeys. Journal of Clinical Investigation 1991; 88: 1995-2002.
163. Folsom AR, Wu KK, Davis CE et al. Population correlates of plasma fibrinogen and factor VII, putative cardiac risk factors. Atherosclerosis 1991; 91: 191-205.
164. Lee AJ, Lowe GOD, Smith WCS & Turnstall-Pedoe H. Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy. British Journal of Haematology 1993; 83: 616-621.
165. Scarabin PY, Vissac AM, Kirzin JM et al. Population correlates of coagulation factor VII: importance of age, sex, and menopausal status as determinants of activated factor VII. Arteriosclerosis, Thrombosis, and Vascular Biology 1996; 16: 1170-1176.
166. Nabulsi AA, Folsom AR, White A et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. New England Journal of Medicine 1993; 328: 1069-1075.
167. Meilahn EN, Kuller LH, Matthews KA & Kiss JE. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Annals of Epidemiology 1992; 2: 445-455.
168. Kroon U-B, Silfverstolpe G & Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thrombosis and Haemostasis 1994; 71: 420-423.
169. Sporrong T, Mattsson L-A, Samsioe G et al. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. British Journal of Obstetrics and Gynaecology 1990; 97: 939-944.
170. Gebara OC, Mittleman MA, Sutherland P et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91: 1952-1958.
171. Shahar E, Folsom AR, Salomaa VV et al for the Atherosclerosis Risk in Communities ARIC Study Investigators. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Circulation 1996; 93: 1970-1975.
172. Mitchell HC. Effect of estrogen and a progestogen on platelet adhesiveness and aggregation in rabbits. Journal of Laboratory and Clinical Medicine 1974; 83: 79-89.
173. Aune B, Oian P, Omsjo I & Osterud B. Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood - a beneficial effect on atherogenesis and thrombus formation? American Journal of Obstetrics and Gynecology 1995; 173: 816-820.
174. Bar J, Tepper R, Fuchs J et al. The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstetrics and Gynecology 1993; 81: 261-264.
175. Chang W-C, Nakao J, Orimo H & Murota S-L. Stimulation of prostaglandin cyclooxygenase and prostacyclin synthetase activities by estradiol in rat aortic smooth muscle cells. Biochimica et Biophysica Acta 1980; 620: 472-482.
176. Seillan C, Ody C, Russo-Marie F & Duval D. Differential effects of sex steroids on prostaglandin secretion by male and female cultured piglet endothelial cells. Prostaglandins 1983; 26: 3-12.
177. Witter FR & DiBlasi MC. Effect of steroid hormones on arachidonic acid metabolites of endothelial cells. Obstetrics and Gynecology 1984; 63: 747-751.
178. David M, Griesmacher A & Muller MM. 17-alpha-ethinylestradiol decreses production and release of prostacyclin, in cultured human umbilical vein endothelial cells. Prostaglandins 1989; 38: 431-438.
179. Fogelberg M, Vesterqvist O, Diczfalusy U & Henriksson P. Experimental atherosclerosis: effects of oestrogen and atherosclerosis on thromboxane and prostacyclin formation. European Journal of Clinical Investigation 1990; 20: 105-110.
180. Redmond EM, Cherian MN & Wetzel RC. 17β-estradiol inhibits flow- and acute hypoxia-induced prostacyclin release from perfused endocardial endothelial cells. Circulation 1994; 90: 2519-2524.
181. Hulley S, Grady D, Bush T et al. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Journal of the American Medical Association 1998; 280: 605-613.
182. Altura BM & Altura BT. Influence of sex hormones, oral contraceptives and pregnancy on vascular muscle and its reactivity. In Carrier O & Shibata S (eds) Factors Influencing Vascular Reactivity, pp 221-254. Tokyo: Ygaku-Shoin, 1977.
183. Gisclard V, Flavahan NA & Vanhoutte PM. Alpha adrenergic responses of blood vessels of rabbits after ovariectomy and administration of 17 beta estradiol. Journal of Pharmacology and Experimental Therapeutics 1988; 240: 466-470.
184. Colucci WS, Giambrone MA, McLaughlin MK et al. Increased vascular catecholamine sensitivity and alpha adrenergic receptor affinity in female and estrogen treated male rats. Circulation Research 1982; 50: 805-811.
185. Barone S, Panek D, Bennett L et al. The influence of oestrogen and oestrogen metabolites on the sensitivity of the isolated rabbit aorta to catecholamines. Archives of Pharmacology 1987; 335: 513-520.
186. Ganger KF, Vyas S, Whitehead M et al. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991; 338: 839-842.
187. Lobo RA. Cardiovascular implications of estrogen replacement therapy. Obstetrics and Gynecology 1990; 75 (supplement): 18S-25S.
188. Proudler AJ, Ahmed AI, Crook D et al. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 1995; 346: 89-90.
189. Barrett-Connor E & Laakso M. Ischemic heart disease risk in postmenopausal women: Effects of estrogen use on glucose and insulin levels. Arteriosclerosis 1990; 10: 531-534.
190. Abraham GE & Maroulis GB. Affect of exogenous estrogen on serum pregnenolone, cortisol and androgens in postmenopausal women. Obstetrics and Gynecology 1975; 45: 271-274.
191. Magness RR & Rosenfeld CR. Local and systemic estradiol-17β: effects on uterine and systemic vasodilation. American Journal of Physiology 1989; 256: E536-E542.
192. Magness RR, Oarker CR & Rosenfeld CR. Systemic and uterine responses to chronic infusion of estradiol-17β. American Journal of Physiology 1993; 265: E690-E698.
193. Killam AO, Rosefeld CR, Battaglia CR et al. Effect of estrogens on the uterine blood flow of oophorectomized ewes. American Journal of Obstetrics and Gynecology 1973; 115: 1045-1052.
194. Gorodeski GI, Sheean LA & Utian WH. Sex hormone modulation of flow velocity in the parametrial artery of the pregnant rat. American Journal of Physiology 1995; 268: R614-R624.
195. Gisclard V, Miller VM & Vanhoutte PM. Effect of 17β-estradiol on endothelium-dependent responses in the rabbit. Journal of Pharmacology and Experimental Therapeutics 1988; 244: 19-22.
196. Lieberman EH, Gerhard MD, Uehata A et al. Estrogen improves endothelium-dependent flow-mediated vasodilation in postmenopausal women. Annals of Internal Medicine 1994; 21: 936-941.
197. Gilligan DM, Badar DM, Panza JA et al. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. American Journal of Cardiology 1995; 75: 264-268.
198. Gorodeski GI, Yang T, Levy MN et al. Effects of estrogen in vivo on coronary vascular resistance in perfused rabbit hearts. American Journal of Physiology 1995; 269: R1333-R1338.
199. Fischer GM, Cherian K & Swain ML. Increased synthesis of aortic collagen and elastin in experimental atherosclerosis: inhibition by contraceptive steroids. Atherosclerosis 1981; 39: 463-476.
200. Fischer GM & Swain ML. Effects of estradiol and progesterone on the increased synthesis of collagen in atherosclerotic rabbit aortas. Atherosclerosis 1985; 54: 177-185.
201. Morales DE, McGowan KA & Grant DS. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 1995; 91: 755-763.
202. Caulin-Glaser T, Watson CA & Bender JR. Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression. Journal of Clinical Investigation 1996; 98: 36-42.
203. Kolodgic FD, Jacob A, Wilson PS et al. Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. American Journal of Pathology 1996; 148: 969-976.
204. Schnaper HW, McGowan KA, Kim-Schulze S & Cid MC. Oestrogen and endothelial cell angiogenic activity. Clinical & Experimental Pharmacology and Physiology 1996; 23: 247-250.
205. Suzuki A, Mizuno K, Ino Y et al. Effects of 17 beta-estradiol and progesterone on growth-factor-induced proliferation and migration in human female aortic smooth muscle cells in vitro. Cardiovascular Research 1996; 32: 516-523.
206. Morey AK, Pedram A, Razandi M et al. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology 1997; 138: 3330-3339.
207. Gilligan DM, Quyyumi AA & Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994; 9: 2545-2551.
208. Riedel M, Oeltermann A, Mugge A et al. Vascular responses to 17 beta-oestradiol in postmenopausal women. European Journal of Clinical Investigation 1995; 25: 44-47.
209. Rajkumar C, Kingwell BA, Cameron JD et al. Hormonal therapy increases arterial compliance in postmenopausal women. Journal of the American College of Cardiology 1997; 30: 350-356.
210. Wellman GC, Brayden JE & Nelson MT. A proposed mechanism for the cardioprotective effect of oestrogen in women: enhanced endothelial nitric oxide release decreases coronary artery reactivity. Clinical and Experimental Pharmacology and Physiology 1996; 23: 260-266.
211. Hayashi T, Fukuto JM, Ignarro LJ & Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implication for atherosclerosis. Proceedings of the National Academy of Sciences of the USA 1992; 89: 11 259-11 263.
212. Farhat MY, Lavigne MC & Ramwell PW. The vascular protective effects of estrogen. FASEB Journal 1996; 10: 615-624.
213. Miller VM, Barber DA, Fenton AM et al. Gender differences in response to endothelin-1 in coronary arteries: transcription, receptors and calcium regulation. Clinical and Experimental Pharmacology and Physiology 1996; 23: 256-259.
214. Osborne JA, Siegman MJ, Sedar AW et al. Lack of endothelium dependent relaxation in coronary resistance arteries of cholesterol-fed rabbits. American Journal of Physiology 1989; 256: 6591-6597.
215. Mugge A, Riedel M, Barton M et al. Endothelium independent relaxation of human coronary arteries by 177beta;-oestradiol in vitro. Cardiovascular Research 1993; 27: 1939-1942.
216. Chester AH, Jiang C, Borland JA et al. Oestrogen relaxes human epicardial coronary arteries through non-endothelium-dependent mechanisms. Coronary Artery Disease 1997; 6: 417-422.
217. Vedernikov YP, Liao QP, Jain V et al. Effect of chronic treatment with 17beta-estradiol and progesterone on endothelium-dependent and endothelium-independent relaxation in isolated aortic rings from ovariectomized rats. American Journal of Obstetrics and Gynecology 1997; 176: 603-608.
218. Fregly MJ & Thrasher TN. Response of heart rate to acute administration of isoproterenol in rats treated chronically with norethynodrel, ethinyl estradiol, and both combined. Endocrinology 1997; 100: 148-154.
219. Levin RM, Shofer FS & Wein AJ. Estrogen-induced alterations in the autonomic responces of the rabbit urinary bladder. Journal of Pharmacology and Experimental Therapeutics 1980; 215: 614-618.
220. Egozi Y & Kloog Y. Muscarinic receptors in the preoptic area are sensitive to 17 beta-estradiol during the critical period. Neuroendocrinology 1985; 40: 385-392.
221. 2 in porcine coronary artery. Circulation 1995; 91: 2619-2626.
222. Cho M, Ziats NP, Abdul-Karim F et al. Effects of estrogen on tight junctional resistance in cultured human umbilical vein endothelial cells. Journal of the Society for Gynecologic Investigation 1998; 5: 260-270.
223. Cho MM, Ziats NP, Pal D et al. Estrogen modulates paracellular permeability of human umbilical vein endothelial cells by eNOS and iNOS related mechanisms. American Journal of Physiology 1999; 276: C337-C349.
224. Hough JL & Zilversmith DB. Effect of 17 beta estradiol on aortic cholesterol content and metabolism in cholesterol-fed rabbits. Arteriosclerosis 1986; 6: 57-63.
225. Adams MR, Kaplan JR, Manuck SB et al. Inhibition of coronary artery atherosclerosis by 17 beta estradiol in ovariectomized monkeys. Arteriosclerosis 1990; 10: 1051-1057.
226. Cheng LP, Kuwahara M, Jacobsson J & Foeg ML. Inhibition of myointimal hyperplasia and macrophage infiltration by estradiol in aorta allografts. Transplantation 1991; 52: 967-972.
227. Wagner JD, Clarkson TB, St Clair RW et al. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. Journal of Clinical Investigation 1991; 88: 1995-2002.
228. Foegh ML, Asotra S, Howell MH & Ramwell PW. Estradiol inhibition of arterial neointimal hyperplasia after balloon injury. Journal of Vascular Surgery 1994; 19: 722-726.
229. Wagner JD, Schwenke DC, Zhang L et al. Effects of short-term hormone replacement therapies on low-density lipoprotein metabolism in cynomolgus monkeys. Arteriosclerosis Thrombosis and Vascular Biology 1997; 17: 1128-1134.
230. Rosenfeld ME, Khoo JC, Miller E et al. Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of low density lipoproteins and contain oxidation specific lipid protein adducts. Journal of Clinical Investigation 1991; 87: 90-99.
231. Regnstrom J, Nilsson J, Tornvall P et al. Susceptibility to low density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992; 339: 1183-1186.
232. Mitchinson MJ & Ball RY. Macrophages and atherogenesis. Lancet 1987; i: 146-148.
233. Barrowcliffe TW, Gutteridge JM & Gray E. Oxygen radicals, lipid peroxidation and the coagulation system. Agents Actions 1987; 22: 347-348.
234. Editorial: Atherosclerosis goes to the wall. Lancet 1992; 339: 647-648.
235. Davies SW, Marchant B, Lyons JP et al. Irregular coronary lesion morphology after thrombolysis predicts early clinical instability. Journal of the American College of Cardiology 1991; 18: 669-674.
236. Little WC. Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction. American Journal of Cardiology 1990; 66: 44G-47G.
237. Moise A, Lesperance J, Theroux P et al. Clinical and angiographic predictors of new total coronary occlusion in coronary artery disease: analysis of 313 nonoperated patients. American Journal of Cardiology 1984; 54: 1176-1181.
238. Tomanek RJ. Age as a modulator of coronary capillary angiogenesis. Circulation 1992; 86: 320-321.
239. Sack MN, Rader DJ & Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994; 343: 269-270.
240. Gorodeski GI. Mechanisms of action for estrogen in cardio-protection. In Wren BG (ed.) Progress in the Management of Menopause, pp 402-418. Carnforth, Lanes, UK: The Parthenon Publishing group Limited, 1997.
241. Gallagher LJ & Sloane BF. Effect of estrogen on lysosomal enzyme activities in rat heart. Proceedings of the Society for Experimental Biology and Medicine 1984; 177: 428-433.
242. Carrington LJ & Bailey CJ. Effects of natural and synthetic estrogens and progestins on glycogen deposition in female mice. Hormone Research 1985; 21: 199-203.
243. Payne RM, Friedman DL, Grant JW et al. Creatine kinase isoenzymes are highly regulated during pregnancy in rat uterus and placenta. American Journal of Physiology 1993; 265: E624-E235.
244. Weiner CP, Lizasoain J, Baylis SA et al. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proceedings of the National Academy of Sciences of the USA 1994; 91: 5212-5216.
245. Shiverick KT, Hutchins K, Kikta DC et al. Effects of chronic administration of mestranol on alpha and beta adrenergic Responsiveness in female rats. Journal of Pharmacology and Experimental Therapeutics 1983; 226: 362-367.
246. Pines A, Fisman EZ, Levo Y et al. The effects of hormone replacement therapy in nomal postmenopausal women: measurements of Doppler-derived parameters of aortic flow. American Journal of Obstetrics and Gynecology 1991; 164: 806-812.
247. Davis LE, Magness RR & Rosenfeld CR. Role of angiotensin II and α-adrenergic receptors during estrogen-induced vasodilation in ewes. American Journal of Physiology 1992; 263: E837-E843.
248. Pines A, Fisman EZ, Shemesh J et al. Menopause related changes in left ventricular function in healthy women. Cardiology 1992; 80: 413-416.
249. Blumenthal RS, Brinker JA & Resar JR. Long-term estrogen therapy abolishes acute estrogen-induced coronary flow augmentation in postmenopausal women. American Heart Journal 1997; 133: 323-328.
250. Pines A, Fisman EZ, Shapira I et al. Exercise echocardiography in postmenopausal hormone users with mild systemic hypertension. American Journal of Cardiology 1996; 78: 1385-1389.
251. Malhotra A, Buttride P & Scheuer J. Effect of sex hormones on development of physiological and pathological cardiac hypertrophy in male and female rats. American Journal of Physiology 1990; 259: H866-H871.
252. Schaible TF, Malhotra A, Ciambrone G & Scheuer J. The effects of gonadectomy on left ventricular function and cardiac contractile proteins in male and female rats. Circulation Research 1984; 58: 38-49.
253. Scheuer J, Malhotra A, Schaible TF & Capasso J. Effects of gonadectomy and hormonal replacement on rat hearts. Circulation Research 1987; 61: 12-19.
254. Colucci WS, Gimbrone MA & Alexander RW. Regulation of myocardial and vascular α-adrenergic receptor affinity. Circulation Research 1984; 55: 78-88.
255. Schwarz P, Diem R, Dun NJ & Forstermann U. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circulation Research 1995; 77: 841-848.
256. Jennings RB, Steenbergen C Jr & Reimer KA. Myocardial ischemia and reperfusion. Monographs in Pathology 1995; 37: 47-80.
257. Delyani JA, Murohara T, Nossuli TO & Lefer AM. Protection from myocardial reperfusion injury by acute administraiton of 17β-estradiol. Journal of Molecular and Cellular Cardiology 1996; 28: 1001-1008.
258. Hale SL, Birnbaum Y & Kloner RA. β-estradiol, but not α-estradiol, reduces myocardial necrosis in rabbits after ischemia and reperfusion. American Heart Journal 1996; 132: 258-262.
259. McHugh NA, Cook SM, Schairer JL et al. Ischemia- and reperfusion-induced ventricular arrhythmias in dogs: effects of estrogen. American Journal of Physiology 1995; 268: H2569-H2573.
260. Kim YD, Farhat MY, Myers AK et al. Beta estradiol regulation of myocardial glutathione and its role in protection against myocardial stunning in dogs. Journal of Cardiovascular Pharmacology 1998; 32: 457-465.
261. Kim YD, Chen B, Beauregard J et al. 17-beta-estradiol prevents dysfunciton of canine coronary endothelium and myocardium and reperfusion arrhythmias after brief ischemia/reperfusion. Circulation 1996; 94: 2901-2908.
262. Martin LG, Brenner GM, Jarolim KL et al. Effects of sex steroids on myocardial anoxic resistance. Proceedings of the Society for Experimental Medicine and Biology 1993; 202: 288-294.
263. Gorodeski GI, Levy MN, Yang T et al. Beneficial effects of estrogen on cardiac stunning in female rabbits. Journal of the Society for Gynecologic Investigation 1999; 6: 80-87.
264. Ames BN, Shigenaga MK & Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proceedings of the National Academy of Sciences of the USA 1993; 90: 7915-7922.
265. Kendall MJ, Rajman I & Maxwell SRJ. Cardioprotective therapeutics drugs used in hypertension, hyperlipidaemia, thromboemolism, arrhythmias, the postmenopausal state and as anti-oxidants. Postgraduate Medical Journal 1994: 70: 329-343.
266. Sato I, Morita I, Kaji K et al. Reduction of nitric oxide producing activity associated with in vitro aging in cultured human umbilical vein. Biochemical and Biophysical Research Communications 1993; 195: 1070-1076.
267. Brunet J, Boily MJ, Cordeau S & Des Rosiers C. Effects of N-acetylcysteine in the rat heart reperfused after low-flow ischemia: evidence for a direct scavenging of hydroxyl radicals and a nitric oxide-dependent increase in coronary flow. Free Radical Biology and Medicine 1995; 19: 627-638.
268. Padwick ML, Pryse-Davis J & Whitehead MI. A simple method for determining the optimal dosage of progestin in postmenopausal women receiving estrogens. New England Journal of Medicine 1986; 315: 930.
269. Henderson BF, Pike MC, Ross RR et al. Re-evaluating the role of progestogen therapy after the menopause. Fertility and Sterility 1988; 49 (supplement): 9S-15S.
270. La Rosa JC. The varying effects of progestins on lipid levels and cardiovascular disease. American Journal of Obstetrics and Gynecology 1988; 158: 1621-1629.
271. Sherwin BB & Gelfand MM. A prospective one year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids. Obstetrics and Gynecology 1989; 73: 759-766.
272. Knopp RH. Effects of sex steroid hormones on lipoprotein levels in pre and postmenopausal women. Canadian Journal of Cardiology 1990; 6 (supplement): 31B-35B.
273. Cano A, Fernandes H, Serrano S & Mahiques P. Effect of continuous oestradiol-medroxyprogesterone administration on plasma lipids and lipoproteins. Maturitas 1991; 13: 35-42.
274. Crook D & Stevenson JC. Progestogens, lipid metabolism and hormone replacement therapy. British Journal of Obstetrics and Gynaecology 1991; 98: 749-750.
275. Lobo RA, Pickar JH, Wild RA et al for the Menopause Study Group. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstetrics and Gynecology 1994; 84: 987-995.
276. Adams MR, Register TC, Golden DL et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 1997; 17: 217-221.
277. Yancey MK, Hannan CJ, Plymate SR et al. Serum lipids and lipoproteins in continuous or cyclic medroxyprogesterone acetate treatment in postmenopausal women treated with conjugated estrogens. Fertility and Sterility 1990 54: 778-782.
278. Haarbo J, Hassager C, Jensen SB et al. Serum lipids, lipoproteins and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-Nortestosterone derivatives or 17-hydroxy progesterone derivatives. American Journal of Medicine 1991; 90: 584-589.
279. Lee WS, Harder JA, Yoshizumi M et al. Progesterone inhibits arterial smooth muscle cell proliferation. Nature Medicine 1997; 3: 1005-1008.
280. Sarrel PM. How progestins compromise the cardiovascular effects of estrogens. Menopause 1995; 2: 187-190.
281. Miyagawa K, Rosch J, Stanczyk F & Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nature Medicine 1997; 3: 324-327.
282. Gorodeski GI, Yang T, Levy MN et al. Modulation of coronary vascular resistance in female rabbits by estrogen and progesterone. Journal of the Society of Gynecological Investigation 1998; 5: 197-202.
283. Ettinger B. Hormone replacement and coronary heart disease. Obstetrics and Gynecology Clinics of North America 1990; 17: 741-757.
284. Makila UM, Wahlberg L, Vlinikkal L & Ylikorkala O. Regulation of prostacyclin and thromboxane production by human umbilical vessels: the effect of estradiol and progesterone in a superfusion model. Prostaglandins, Leukotriens and Medicine 1982; 8: 115-124.
285. Stuenkel CA. Women and heart disease. Proceedings, Annual Meeting of the Medical Section American Council Life Insurance 1994; 203-215.
286. Ready AE, Drinkwater DT, Ducas J et al. Walking program reduces elevated cholesterol in women in postmenopause. Canadian Journal of Cardiology 1995; 11: 905-912.
287. Binder EF, Birge SJ & Kohrt WM. Effects of endurance exercise and hormone replacement therapy on serum lipids in older women. Journal of the American Geriatric Society 1996; 44: 231-236.
288. Bush TL. Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. European Heart Journal 1996; 17 (supplement D): 9-14.
289. Playford DA & Watts GF. Management of lipid disorders in the elderly. Drugs & Aging 1997; 10: 444-462.
290. Kushi LH, Folsom AR, Prineas RJ et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. New England Journal of Medicine 1996; 334: 1156-1162.
291. Sullivan JM. Practical aspects of preventing and managing atherosclerotic disease in post-menopausal women. European Heart journal 1996; 17 (supplement D): 32-37.
292. Goldstein MR. Evidence supporting cholesterol-lowering therapy for postmenopausal women with heart disease. Journal of the American Medical Association 1997; 278: 633-634.
293. Grundy SM. Primary prevention of coronary heart disease: role of cholesterol control in the United States. Journal of Internal Medicine 1997; 241: 295-306.
294. Kushi LH, Fee RM, Folsom AR et al. Physical activity and mortality in postmenopausal women. Journal of the American Medical Association 1997; 277: 1287-1292.
295. Mosca L, Manson JE, Sutherland SE et al. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96: 2468-2482.
296. Nicklas BJ, Katzel LI, Bunyard LB et al. Effects of an American Heart Association diet and weight loss on lipoprotein lipids in obese, postmenopausal women. American Journal of Clinical Nutrition 1997; 66: 853-859.
297. Schrott HG, Bittner V, Vittinghoff E et al. The Heart and Estrogen/Progestin Replacement Study (HERS). Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. Journal of the American Medical Association 1997; 277: 1281-1286.
298. Lonnqvist F, Arner P, Nordfors L & Schalling M. Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nature Medicine 1995; 1: 950-953.
299. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. European Heart Journal 2001; 22: 554-572.
300. Bandyopadhyay S, Bayer AJ & O'Mahony MS. Age and gender bias in statin trials. Quarterly Journal of Medicine 2001; 94: 127-132.
301. Dayspring TD. Prevention of a first myocardial infarction. Journal of Clinical Pharmacology 2001; 41: 359-367.
302. Lloyd-Jones DM, O'Donnell CJ, D'Agostino RB et al. Applicability of cholesterol-lowering primary prevention trials to a general population: the Framingham heart study. Archives of Internal Medicine 2001; 161: 949-954.
303. Chae CU, Ridker PM & Manson JE. Postmenopausal hormone replacement therapy and cardiovascular disease. Thrombosis & Haemostasis 1997; 78: 770-780.
304. Ettinger B, Friedman GD, Bush T & Quesenbury CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstetrics and Gynecology 1996; 87: 6-12.
305. Folsom AR, Mink PJ, Sellers TA et al. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. American Journal of Public Health 1995; 85: 1128-1132.
306. Radford NB. Southwestern Internal Medicine Conference: postmenopausal estrogen supplementation: a cardiologist's perspective. American Journal of Medical Science 1994; 308: 63-73.
307. Nathan L & Chaudhuri G. Estrogens and atherosclerosis (review). Annual Review of Pharmacology & Toxicology 1997; 37: 477-515.
308. Moerman CJ, Witteman JC, Collette HJ et al. Hormone replacement therapy: a useful tool in the prevention of coronary artery disease in postmenopausal women? European Heart Journal 1996; 17: 658-666.
309. Guetta V & Cannon RO. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 1996; 93: 1928-1937.
310. Rossouw JE. Estrogens for the prevention of coronary heart disease: putting the brakes on the bandwagon. Circulation 1996; 94: 2982-2985.
311. Grodstein F, Manson JE, Colditz GA et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Annals of Internal Medicine 2000; 133: 933-941.
312. Herrington DM, Reboussin DM, Klein KP et al. The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. Controlled Clinical Trials 2000; 21: 257-285.
313. Heckbert SR, Kaplan RC, Weiss NS et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Archives of Internal Medicine 2001; 161: 1709-1713.
314. Spinler SA, Hilleman DE, Cheng JW et al. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines. Annals of Pharmacotherapy 2001; 35: 589-617.
315. Bush T. Beyond HERS: some (not so) random thoughts on randomized clinical trials. International Journal of Fertility and Womens Medicine 2001; 46: 55-59.
316. Whitehead M. The need for continuing education of the prescriber. Climacteric 2000; 3 (supplement 2): 28-32.
317. Coulam CB, Adamson SC & Annegers JF. Incidence of premature ovarian failure. Obstetrics and Gynecology 1986; 67: 604-606.
318. Gorodeski GI. Premature menopause. Menopause Management 1997; 6: 10-17.
319. Eaker ED & Castelli WP. Coronary heart disease and its risk factors among women in the Framingham Study. In Eaker E et al (eds) Coronary Heart Disease in Women, pp 122-132. New York: Haymarket Doyma, 1987.